BeiGene Ltd.

Durvalumab improved progression-free survival (PFS) over placebo in patients with locally advanced, unresectable non–small cell lung cancer (NSCLC) after platinum-based chemoradiotherapy (CRT), with a 25% reduction in risk of disease progression or death. Subgroup analysis showed consistent PFS benefit regardless of CRT type, and a trend toward improved overall survival (OS) was observed. PACIFIC-5 supports consolidation immunotherapy after either concurrent or sequential CRT.

BeiGene expanded oncology trials in Brazil, establishing a local team in 2021. The company focused on partnerships, regulatory coordination, and efficient study start-up, achieving rapid approvals and high patient enrollment. BeiGene aims to scale up operations and introduce Phase 1 studies in Brazil.

Brazil faces significant cancer challenges, including disparities in care and limited access to advanced treatments. BeiGene established a local clinical operations team in 2022, launching over 10 clinical studies and enrolling over 200 patients. Brazil's position as a critical hub for oncology research in Latin America is solidified through collaboration with investigators, clinical sites, and regulators, leveraging a CRO-free operational model to drive cost efficiency and accelerate trial timelines.

Repare Therapeutics shares drop 47% after phase I data release. EMA recommends 17 drugs for approval, including Welireg and Emcitate. Beigene strikes $1.5B deal for MAT2A inhibitor. Bicycle Therapeutics stock drops 30% following mixed trial results. Helmholtz Institute discovers new insulin receptor. GC Biopharma to acquire Abo Holdings for ₩138B.

CSPC Pharmaceutical Group entered an exclusive license agreement with BeiGene for SYH2039, a cancer drug targeting MTAP-deficient tumors, with $150M upfront and up to $1.685B in milestone payments plus royalties.

The inMIND trial showed Monjuvi + Rituxan + Revlimid improved progression-free survival (PFS) to 22.4 months vs. 13.9 months for placebo in R/R follicular lymphoma. Key secondary endpoints also favored the experimental arm. Monjuvi aims to become a new standard-of-care option, with potential competition from other therapies.

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.

BeiGene presented new data at ASH 2024 showing BRUKINSA reduced progression/death risk by 71% in treatment-naïve CLL patients. Sonrotoclax + BRUKINSA achieved 99% overall response rate and 92% best uMRD rate. BTK degrader BGB-16673 showed 94% overall response rate at 200mg dose.